Cargando…
Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study
BACKGROUND: This study analyzed the efficacy and safety of neoadjuvant chemotherapy with liposomal paclitaxel plus platinum in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC). METHODS: The data of patients with locally advanced resectable ESCC (staging cT2N + M0,...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930492/ https://www.ncbi.nlm.nih.gov/pubmed/35118824 http://dx.doi.org/10.1111/1759-7714.14328 |
_version_ | 1784671072323371008 |
---|---|
author | Wang, Wenzhong Yi, Yang Jia, Yinghui Dong, Xiaoxin Zhang, Junxia Song, Xiaomeng Song, Yan |
author_facet | Wang, Wenzhong Yi, Yang Jia, Yinghui Dong, Xiaoxin Zhang, Junxia Song, Xiaomeng Song, Yan |
author_sort | Wang, Wenzhong |
collection | PubMed |
description | BACKGROUND: This study analyzed the efficacy and safety of neoadjuvant chemotherapy with liposomal paclitaxel plus platinum in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC). METHODS: The data of patients with locally advanced resectable ESCC (staging cT2N + M0, cT3‐4aNanyM0, IA‐IVA) who received preoperative chemotherapy with liposomal paclitaxel plus platinum (cisplatin, nedaplatin or carboplatin) in HuanXing Cancer Hospital from July 2018 to October 2019 were collected. The primary endpoint of this study was R0 resection rate, and secondary endpoints were pathological complete response (pCR) rate, 1‐ and 2‐year overall survival (OS) rate, 1‐year and 18‐month disease‐free survival (DFS) rate, and safety. RESULTS: A total of 32 eligible patients were included in this study. All patients received neoadjuvant chemotherapy and surgery. The R0 resection rate was 93.8%, the pCR rate was 12.5%, and down‐staging was achieved in 14 patients (47.8%). Median follow‐up was 31.0 months (95% confidence interval [CI] 30.1–31.9 months). The 1‐ and 2‐year OS rates were 96.9% and 78.1%, and the 1‐year and 18‐month DFS rates were 86.7% and 76.7%, respectively. The median DFS and OS were not reached. The incidence rate of neoadjuvant chemotherapy related grade 3–4 adverse events was 21.9%, including neutropenia (21.9%) and leukopenia (9.4%). CONCLUSIONS: The results of this study suggest that liposomal paclitaxel combined with platinum as neoadjuvant chemotherapy can provide satisfactory R0 resection rate and survival rate, and significant tumor down‐staging effect for patients with locally advanced resectable ESCC, with safety profile. |
format | Online Article Text |
id | pubmed-8930492 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-89304922022-03-24 Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study Wang, Wenzhong Yi, Yang Jia, Yinghui Dong, Xiaoxin Zhang, Junxia Song, Xiaomeng Song, Yan Thorac Cancer Original Articles BACKGROUND: This study analyzed the efficacy and safety of neoadjuvant chemotherapy with liposomal paclitaxel plus platinum in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC). METHODS: The data of patients with locally advanced resectable ESCC (staging cT2N + M0, cT3‐4aNanyM0, IA‐IVA) who received preoperative chemotherapy with liposomal paclitaxel plus platinum (cisplatin, nedaplatin or carboplatin) in HuanXing Cancer Hospital from July 2018 to October 2019 were collected. The primary endpoint of this study was R0 resection rate, and secondary endpoints were pathological complete response (pCR) rate, 1‐ and 2‐year overall survival (OS) rate, 1‐year and 18‐month disease‐free survival (DFS) rate, and safety. RESULTS: A total of 32 eligible patients were included in this study. All patients received neoadjuvant chemotherapy and surgery. The R0 resection rate was 93.8%, the pCR rate was 12.5%, and down‐staging was achieved in 14 patients (47.8%). Median follow‐up was 31.0 months (95% confidence interval [CI] 30.1–31.9 months). The 1‐ and 2‐year OS rates were 96.9% and 78.1%, and the 1‐year and 18‐month DFS rates were 86.7% and 76.7%, respectively. The median DFS and OS were not reached. The incidence rate of neoadjuvant chemotherapy related grade 3–4 adverse events was 21.9%, including neutropenia (21.9%) and leukopenia (9.4%). CONCLUSIONS: The results of this study suggest that liposomal paclitaxel combined with platinum as neoadjuvant chemotherapy can provide satisfactory R0 resection rate and survival rate, and significant tumor down‐staging effect for patients with locally advanced resectable ESCC, with safety profile. John Wiley & Sons Australia, Ltd 2022-02-04 2022-03 /pmc/articles/PMC8930492/ /pubmed/35118824 http://dx.doi.org/10.1111/1759-7714.14328 Text en © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Wang, Wenzhong Yi, Yang Jia, Yinghui Dong, Xiaoxin Zhang, Junxia Song, Xiaomeng Song, Yan Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study |
title | Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study |
title_full | Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study |
title_fullStr | Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study |
title_full_unstemmed | Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study |
title_short | Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study |
title_sort | neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: results from a retrospective study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930492/ https://www.ncbi.nlm.nih.gov/pubmed/35118824 http://dx.doi.org/10.1111/1759-7714.14328 |
work_keys_str_mv | AT wangwenzhong neoadjuvantchemotherapywithliposomalpaclitaxelplusplatinumforlocallyadvancedesophagealsquamouscellcancerresultsfromaretrospectivestudy AT yiyang neoadjuvantchemotherapywithliposomalpaclitaxelplusplatinumforlocallyadvancedesophagealsquamouscellcancerresultsfromaretrospectivestudy AT jiayinghui neoadjuvantchemotherapywithliposomalpaclitaxelplusplatinumforlocallyadvancedesophagealsquamouscellcancerresultsfromaretrospectivestudy AT dongxiaoxin neoadjuvantchemotherapywithliposomalpaclitaxelplusplatinumforlocallyadvancedesophagealsquamouscellcancerresultsfromaretrospectivestudy AT zhangjunxia neoadjuvantchemotherapywithliposomalpaclitaxelplusplatinumforlocallyadvancedesophagealsquamouscellcancerresultsfromaretrospectivestudy AT songxiaomeng neoadjuvantchemotherapywithliposomalpaclitaxelplusplatinumforlocallyadvancedesophagealsquamouscellcancerresultsfromaretrospectivestudy AT songyan neoadjuvantchemotherapywithliposomalpaclitaxelplusplatinumforlocallyadvancedesophagealsquamouscellcancerresultsfromaretrospectivestudy |